Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2020-07-11
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well lenalidomide works in combination with rituximab in
treating participants with stage III-IV non-Hodgkin lymphoma that is growing slowly.
Lenalidomide is designed to change the body's immune system. It may also interfere with the
development of tiny blood vessels that help support tumor growth, which may prevent the
growth of cancer cells. Monoclonal antibodies, such as rituximab, may interfere with the
ability of cancer cells to grow and spread. Giving lenalidomide and rituximab may work better
in participants with indolent non-Hodgkin lymphoma.